The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Open accessAbstract
Purpose: The primary objective of this randomized, multicenter, phase III trial was to investigate whether the addition of irinotecan to the de Gramont infusional fluorouracil (FU)/leucovorin (LV) adjuvant regimen (LV5FU2) would improve disease-free survival (DFS) in patients with stage III colon cancer. Patients and Methods: After curatively intentioned surgery, patients with stage II and III colon cancer were randomly allocated surgery to receive LV5FU2 (LV 200 mg/m 2 as a 2-hour infusion, followed by FU; as a 400 mg/m 2 bolus and then a 600 mg/m 2 continuous infusion over 22 hours, days 1 and 2, every 2 weeks for 12 cycles: de Gramont regimen) with or without irinotecan (180 mg/m 2 as a 30- to 90-minute infusion, day 1, every 2 weeks). In total, 260 (7.9%) of 3,278 patients received an alternative high-dose infusional FU/LV regimen (Arbeitsgemeinschaft Internische Onkologie regimen) with or without irinotecan. Results: The principal efficacy analysis was based on 2,094 treated patients with stage III disease, randomly allocated in the LV5FU2 strata. After a median follow-up of 66.3 months, the 5-year DFS rate was 56.7% with irinotecan/LV5FU2 and 54.3% with LV5FU2 alone (primary end point: log-rank P = .106). Combining irinotecan with LV5FU2 did not significantly improve overall survival in this patient group compared with LV5FU2 alone (5-year rate 73.6% v 71.3%, respectively; log-rank P = .094). The addition of irinotecan to LV5FU2 was associated with an increased incidence of grade 3 to 4 GI events and neutropenia. Conclusion: Irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival in patients with stage III colon cancer compared with LV5FU2 alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Self-citationK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Self-citationColon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,599
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Self-citationEfficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Self-citationSargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L. A., & Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2144 · Cited by 449
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Self-citationHaller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., & Mayer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5686 · Cited by 391
Köhne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Reichardt, P., Rückle-Lanz, H., Frickhofen, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.546 · Cited by 331
Self-citationSargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4323 · Cited by 240
Self-citationThe Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-38 · Cited by 239
Self-citationYchou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn680 · Cited by 202
Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi116 · Cited by 186
Self-citationAndré, T., Quinaux, E., Louvet, C., Colin, P., Gamelin, E., Bouché, O., Achille, E., Piedbois, P., Tubiana-Mathieu, N., Boutan-Laroze, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2234 · Cited by 168
Self-citationAdjuvant therapy in colon cancer—what, when and how?
Chau, I., & Cunningham, D. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl029 · Cited by 167
Self-citationReintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer
de Gramont, A., Buyse, M. E., Abrahantes, J. C., Burzykowski, T., Quinaux, E., Cervantes, A. M. R., Figer, A., Lledo, G., Flesch, M., Mineur, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4380 · Cited by 146
Self-citationde Gramont, A., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P., Lorenzato, C., & André, T. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4007 · Cited by 131
Self-citation
Cited by
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationDekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
Brenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Self-citationLocalised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Self-citation
Metadata
- Authors
- Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., André, T., Sobrero, A. F., Mini, E., Greil, R., Di Costanzo, F., Collette, L., Cisar, L., Zhang, X., Khayat, D., Bokemeyer, C., Roth, A. D., & Cunningham, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-01
- Volume
- 27
- Issue
- 19
- Pages
- 3117-3125
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159342260
- Cited by
- 467
- References
- 35
- FWCI
- 22.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.